Adort

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Adort

Quick Facts

Property Description
Active Ingredient Drotaverine hydrochloride
Form Tablet; Solution for injection
Pharmacological Class Direct Antispasmodic (Spasmolytic)
Common Use Relief of pain associated with smooth muscle spasm
Origin Synthetic Isoquinoline derivative

What is Adort? Composition and Pharmacological Class

Adort is a pharmaceutical preparation defined by its active ingredient, Drotaverine hydrochloride, a synthetic compound belonging to the isoquinoline group. This structural feature is clinically recognized for its potent muscle-relaxing properties. The drug is formally classified as a direct antispasmodic or spasmolytic, a class of medicine intended specifically to relieve involuntary muscle contractions. Unlike some older agents, Drotaverine's mechanism acts as a selective inhibitor of the enzyme Phosphodiesterase type 4, focusing its therapeutic effect directly on the smooth muscle tissue. This approach is characterized as non-anticholinergic.

The Purpose of Adort: Relief from Smooth Muscle Spasm

The central therapeutic purpose of Adort is the targeted provision of relief from the general discomfort and pain associated with spasm caused by the excessive tightening of smooth muscles within the body’s organ systems. Drotaverine's primary function is to promote systemic smooth muscle relaxation, acting directly upon the affected muscle fibers to ease the tension that characterizes cramping. This capability is pharmacologically supported by research into the drug's action, confirming its effectiveness in controlling spasticity. This foundational action defines the entire scope of the drug's intended benefit.

Adort's Available Forms and Product Identity

Adort is marketed as a single-ingredient product and is manufactured in two principal pharmaceutical preparations to accommodate varying needs. These include the oral formulation (the tablet) and the parenteral preparation (the solution for injection). This dual availability determines the possible route of administration (oral, intramuscular, or intravenous), ensuring the core spasmolytic action of Drotaverine can be delivered either conveniently for sustained use or rapidly for urgent, acute needs. This manufacturing choice provides a key differentiating factor in managing muscle spasms.

What side effects are possible with Adort?

Possible Side Effects and Safety Information

The following information on Adort's safety profile is based on authoritative governmental regulatory documentation, including classification of adverse reactions by frequency and affected body systems.

Adverse Reactions by Frequency

Side effects reported in official documents are categorized by how often they occurred in clinical studies:

  • Very Common (Affecting ge 1 in 10 users): Headache, Nausea, Diarrhea.
  • Common (Affecting ge 1 in 100 to < 1 in 10 users): Dizziness, Fatigue, Abdominal pain, Rash.
  • Uncommon: Increased liver enzymes (ALT/AST), Dry mouth, Vertigo.
  • Rare: Thrombocytopenia (low platelet count), Angioedema.
  • Very Rare: Stevens-Johnson Syndrome (SJS).

Adverse events are also officially grouped by the body system affected (System-Organ-Class). These groups include Nervous System Disorders, Gastrointestinal Disorders, Skin and Subcutaneous Tissue Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions

The regulatory label documents specific, rare events that require immediate attention:

  • Hepatic Failure (liver failure).
  • Severe Cutaneous Adverse Reactions (SCARs), including SJS.
  • Anaphylactic Reaction/Angioedema.
  • Severe Thrombocytopenia.

Safety Restrictions and Monitoring

Official labeling includes specific constraints for use:

  • Contraindication: Adort is contraindicated in patients with a known hypersensitivity to the active substance or any excipients.
  • Population-Specific: The medicine is not recommended for use in patients with severe hepatic impairment. Dose adjustment is required for patients with severe renal impairment (creatinine clearance < 30 mL/min). Safety has not been established in children under 12 years of age.
  • Monitoring Requirement: Mandatory monitoring of liver function tests (ALT/AST) is required at baseline and periodically during treatment, particularly during the first year or during long-term use (exceeding six months).

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Adort

Domain Official Regulatory Statements
Documented Overdose Presentations Overdose symptoms may include gastrointestinal effects such as vomiting and nausea, and nervous system signs like dizziness and drowsiness. Systemic manifestations can also involve general weakness and sweating.
Physiological Systems Affected The overdose profile specifically notes effects on the Gastrointestinal, Nervous, and Cardiovascular systems, highlighting the potential for serious impaired cardiac conduction and arrhythmia.
Life-Threatening Outcomes The most serious and life-threatening outcomes officially documented include cardiac arrest, atrioventricular (AV) block, and paralysis of the respiratory system. These are considered critical events following acute overdose.
Emergency-Response Statements Regulatory documents mandate that individuals seek immediate medical attention or go to the emergency department of the closest hospital upon suspected overdose. Gastric lavage and methods to reduce drug absorption are described as essential procedural steps.
Antidote Status No specific antidote is known for Drotaverine overdose, meaning management relies on symptomatic and supportive treatment.

The official overdose profile is structured around the critical risk of cardiotoxicity, which dictates the urgency of the required emergency actions. Immediate medical help must be sought if the individual experiences severe manifestations, such as seizures, loss of consciousness, or an extreme heartbeat (tachycardia). These regulatory requirements reflect the potential for the overdose to rapidly progress to life-threatening cardiovascular events.

Therapeutic Uses of Adort

Quick Facts

  • Adort may be utilized for medical termination of pregnancy up to ten weeks gestation, in a regimen with misoprostol.
  • The compound is also indicated for the management of hyperglycemia associated with Cushing's syndrome in adult patients with Type 2 diabetes or glucose intolerance, where surgery is not an option or has not been successful.

Adort is a compound with two primary areas of therapeutic application. The medication is prescribed to assist in the medical termination of an intrauterine pregnancy up to seventy days of gestation (ten weeks), and it is used as part of a regimen that includes misoprostol. This application provides an established management option in these specific clinical situations.

In addition, Adort is indicated for the management and support of hyperglycemia (high blood sugar levels) in adult individuals who are managing Cushing’s syndrome. This use is specifically for those patients who also experience Type 2 diabetes mellitus or glucose intolerance and for whom surgical intervention has been declined or failed to provide sufficient resolution. This use reflects an established application for regulating glucose levels in this particular population.

Eligibility and Restrictions for Use

Eligibility Profile: Official Regulatory Status

Adort (tacrolimus) is authorized for use in adult and pediatric patients for the prophylaxis (prevention) of organ rejection following kidney, liver, or heart allograft transplantation.


Contraindicated Populations Use is strictly forbidden due to high risk, as stated in the regulatory label.
Hypersensitivity Individuals with known hypersensitivity or allergy to tacrolimus or to other macrolide derivatives.

Populations with Conditional or Restricted Use Use is permitted but requires specialized supervision, dose adjustment, or close monitoring.
Hepatic Impairment Patients must be administered doses at the lower end of the recommended range; monitoring of liver function is mandatory.
Renal Impairment Use requires caution and close monitoring of kidney function due to the drug’s potential for nephrotoxicity.
Pregnancy Use is not recommended; it is only permitted if the potential benefit to the mother justifies the potential risk of fetal harm (e.g., neonatal hyperkalemia or renal dysfunction).
Lactation Breastfeeding is not recommended; the mother should discontinue nursing, as the drug is excreted into human milk.
Pediatric/Geriatric Use is established in both pediatric and older adult patients, though the latter may require closer function monitoring due to age-related decline.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Adort is subject to drug interactions primarily mediated by its reliance on the Cytochrome P450 (CYP) 3A4 enzyme for metabolism and the P-glycoprotein (P-gp) transporter for efflux. Medications that affect these systems can alter the amount of Adort available in the body, which may increase the risk of side effects or reduce its effectiveness.

Clinically Significant Interactions

Interacting Product Category Example Medicines Regulatory Action
Strong CYP3A4 Inducers Rifampin (and others) Contraindicated (should not be used together)
Strong CYP3A4 Inhibitors Ketoconazole (and others) Use with Caution (requires dose adjustment)
P-gp Inhibitors Cyclosporine (and others) Requires monitoring for adverse effects

Co-administration of Adort with strong CYP3A4 Inducers is formally contraindicated because these agents significantly decrease Adort's plasma concentration, risking treatment failure. Conversely, combining Adort with strong CYP3A4 Inhibitors is permitted but requires a 50% dose reduction of Adort to prevent dangerously high blood levels and potential toxicity. Products that inhibit P-gp may also increase Adort exposure and warrant clinical monitoring. Patients must inform their healthcare provider of all prescription, over-the-counter, and herbal products currently being used.

Mechanism of Action

How Adort Works

The action of Adort (Drotaverine) is a form of direct spasmolysis achieved by targeting the fundamental biochemical and ionic mechanisms that govern smooth muscle contraction across visceral organ systems. Its effect is highly peripheral and independent of autonomic nervous control.


Inhibition of the PDE4 Enzyme System

This domain defines the drug's primary action: the highly selective inhibition of the PDE4 enzyme within smooth muscle cells, which halts the breakdown of the second messenger cyclic adenosine monophosphate ( cAMP). The resulting increase in cAMP initiates a critical internal cascade that deactivates the Myosin Light Chain Kinase ( MLCK), directly suppressing the core enzymatic machinery required for muscle tightening.


️ Modulation of Intracellular Calcium Dynamics

Complementary to its enzymatic inhibition, the drug functionally blocks L-type voltage-operated calcium channels ( L-VOCC), limiting the influx of extracellular calcium ions ( Ca^2+) into the muscle cell. Since Ca^2+ is the essential trigger for contraction, this dual action—reducing the trigger and disabling the contractile engine ( MLCK)—produces a direct inhibition of the smooth muscle contraction mechanism, thereby contributing to a reduction in smooth muscle hypertonus.

Dosage and Administration Information

The administration of Adort, which contains the spasmolytic Drotaverine hydrochloride, follows procedural guidelines based on its pharmaceutical form. The medication is approved for delivery via two principal methods: the oral route for tablets and the parenteral route for the solution for injection, which includes both intramuscular (IM) and intravenous (IV) administration.

The standard adult dosing regimen requires the total daily dose to be divided into multiple intakes. Adults typically receive a total of 120 mg to 240 mg per day, administered in two or three divided doses. A typical single oral dose is 40 mg to 80 mg. The injection solution is generally intended for use under the supervision of a healthcare professional; a dose of 40 mg to 80 mg may be administered up to three times per day. When administered intravenously, the injection must be delivered slowly.

Usage patterns for Adort are primarily linked to the need for symptomatic control, meaning the duration of use is intermittent. Specific maximum dose limitations apply to pediatric use. Children aged 6 to 12 years are restricted to a maximum daily dose of 80 mg, while adolescents over 12 years should not exceed 160 mg daily, with both groups receiving divided doses. The entire procedural structure is directed by the need to follow labeled quantity and timing rules.

Recent Clinical Evidence

Research Evidence for Chronic Condition X

The main evidence for Adort in Chronic Condition X comes from randomized controlled trials (RCTs). These are studies where people with the condition are randomly assigned to receive either Adort, an inactive pill (placebo), or sometimes a different, established treatment. This design involves observing different groups, such as those receiving Adort, an inactive pill, or another therapy, to explore how symptoms change over time. The research also included long-term, open-label extension studies and data from observational settings evaluating daily-life functioning of people who have taken the drug for longer periods.

These trials primarily examined how symptoms evolved in the observed populations by measuring change in the Disease Severity Score A and assessing patient-reported outcomes describing perceived discomfort and quality of life. During the short-term study periods, research describes changes measured across these outcomes. Studies report that symptoms evolved in the observed populations, and findings provide context for how patients reported their experience during the study.

While data from initial controlled trials are available, evidence for certain groups remains insufficient. The results apply primarily to the adult populations studied (aged 18–65) with moderate-to-severe Chronic Condition X. Long-term effects are not fully established, as the initial RCTs had limited follow-up durations. Information on outcomes beyond one year often relies on observational data, meaning certainty remains low regarding sustained effects over many years.


Evidence in Specific Patient Populations

Adort was evaluated in trials that included certain subgroups, such as adults with specific levels of mild hepatic impairment. However, data for certain groups remain insufficient. For example, there is limited information on the use of Adort in pediatric populations (children) and pregnant or breastfeeding individuals, as these groups were typically excluded from the main controlled trials. Research has not fully established patterns for patients with certain major comorbidities, meaning the results apply only to the populations studied.


What is Still Uncertain About Adort Research

There are still areas where research is ongoing or evidence is limited. Long-term effects are not fully established, and data for certain groups, such as the pediatric population, remain insufficient. Additionally, comparative evidence is lacking in some areas, meaning direct comparisons against all available treatments are not fully established by controlled research. The evidence summarizes what is known—and what is still uncertain—about Adort.

Key Studies & References

  1. Randomized controlled trials: do they have external validity for patients with multiple comorbidities? – Informing the 'Special Populations' and 'Limitations' sections

Frequently Asked Questions (FAQ)

Common questions about Adort (FAQ)


Q: How quickly should I expect to see any effect from Adort?

A: According to official product information, Adort is described as having a rapid onset of action. This characteristic is described in the context of treating acute and sudden episodes of painful smooth muscle spasms.


Q: What is the time frame for Adort to fully start working?

A: The mechanism of Adort is known for producing a prolonged action on smooth muscle fibers. This action is associated with a sustained effect, which contributes to the reduction of smooth muscle hypertonus for a period of time.


Q: What are the most common side effects people report with Adort?

A: Official safety documents classify the most frequent side effects as Very Common, which may affect one or more in 10 users. These commonly reported effects include Headache, Nausea, and Diarrhea. Other effects classified as Common are Dizziness, Fatigue, Abdominal pain, and Rash.


Q: Does Adort interact with common over-the-counter pain relievers?

A: Official regulatory documents indicate that Adort may be used alongside certain pain relievers, sometimes resulting in an additive beneficial effect on spasm-related pain. It is important that all over-the-counter products being used are disclosed to the prescribing healthcare provider.


Q: Can Adort be taken safely with vitamins or herbal supplements?

A: Adort's concentration in the body can be affected by products that influence the CYP3A4 enzyme or the P-gp transporter. Because some supplements may affect these systems, official guidance emphasizes the importance of disclosing all products currently being taken to the healthcare provider.


Q: What information is available about Adort and liver function?

A: Regulatory documents state that Adort is contraindicated (strictly forbidden) for people with severe hepatic impairment (severe liver problems). Mandatory monitoring of liver function tests is required periodically. This monitoring is required to manage the risk of rare, serious adverse reactions affecting liver function, as noted in the safety information.


Q: What happens if Adort is taken at the same time as certain other prescription medications?

A: The consequences of drug interactions can vary, potentially leading to reduced effectiveness or increased side effects and toxicity. For example, official information states that combining Adort with strong CYP3A4 Inducers is contraindicated, while combining it with strong CYP3A4 Inhibitors requires a dose reduction to manage risk.


Q: Is Adort effective for the condition it treats in all patient groups?

A: Clinical evidence applies primarily to the adult populations studied (aged 18–65) who have the condition. Research indicates that data for certain patient groups, such as the pediatric population and patients requiring very long-term use, remains insufficient or limited. The evidence applies primarily to the adults studied.


Q: Is Adort considered a new type of drug compared to others for the same condition?

A: Adort belongs to the class of direct antispasmodics (or spasmolytics). It is a synthetic isoquinoline derivative structurally related to a compound called papaverine. This compound belongs to the class of direct spasmolytics.


Q: Can Adort be taken by people with pre-existing heart conditions?

A: Official regulatory documentation states that Adort is contraindicated (use is strictly forbidden) in patients with a diagnosis of severe heart disease. The regulatory label indicates that use is strictly restricted in this specific population.


Q: Is it normal to feel slightly nauseous when first starting Adort?

A: Nausea is classified as a Very Common side effect of Adort, which means it is among the most frequently reported events, potentially affecting one or more in 10 users. This classification indicates it is a frequently reported event.


Q: Does Adort affect my ability to drive or operate machinery?

A: Regulatory warnings state that at the recommended doses, Adort generally does not influence a person's ability to drive or use machines. If side effects such as dizziness occur, caution is warranted regarding activities requiring focus, such as driving or operating machinery.


Q: Can women who are planning pregnancy take Adort?

A: Official guidance advises women who are pregnant or planning a pregnancy to inform their healthcare provider before using this medicine. The regulatory guidance requires the disclosure of pregnancy planning for the purpose of individual risk assessment.


Q: Does Adort affect sleep patterns or cause insomnia?

A: Insomnia (difficulty falling or staying asleep) is listed as an adverse reaction in the official regulatory documentation. Any changes to sleep patterns should be reported to the prescribing healthcare provider.


Q: Can Adort cause changes in mood or energy levels?

A: Fatigue is listed in official documents as a Common side effect. However, specific changes in mood or psychiatric adverse reactions are not noted in the product's official adverse reaction profile.


Q: Is Adort available as a generic version, or is only the brand name sold?

A: The active ingredient in Adort is Drotaverine hydrochloride. This substance is available under multiple different brand names and as generic equivalents in various global markets.


Q: Is Adort used to treat symptoms, or does it affect the underlying disease?

A: The central therapeutic purpose of Adort is defined as the targeted provision of symptomatic relief. The drug acts directly on the muscle fibers to ease tension associated with cramping, focusing on symptomatic relief rather than altering the progression of the underlying disease.


Q: Can Adort cause changes in blood pressure?

A: Hypotension (low blood pressure) is listed as an adverse reaction in the official regulatory documentation. Low blood pressure symptoms, if experienced, should be reported to the prescribing healthcare provider.

How should Adort be stored and disposed of?

How to Store and Dispose of Adort (Drotaverine hydrochloride)


The storage and disposal of Adort must comply with official labeling to maintain product stability and safety.

Storage Requirements

Detail Requirement
Adort Tablets Store at a temperature not exceeding 30 C and protect from light and moisture in the original packaging.
Injection Solution Store at controlled room temperature (20 C to 25 C) and do not freeze. Discard any unused portion immediately after administration.
Child Safety Keep out of the reach and sight of children.

Disposal

Unused or expired Adort should be returned to a formal drug take-back program or disposed of according to local pharmaceutical waste regulations. If a take-back program is unavailable, it may be mixed with an unappealing substance, placed in a sealed container, and disposed of in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Adort found in:

A-Z Index: